57
17. Santos AF, Lengruber RB, Soares EA, Jere A, Sprinz E, Martinez AM,
Silveira J, Sion FS, Pathak VK, Soares MA. Conservation patterns of HIV-1
RT connection and RNase H domains: identification of new mutations in
NRTI-treated patients. PLoS ONE. 2008 Mar 12;3(3):e1781.
18. Kempf DJ, Isaacson JD, King MS, Brun SC, Xu Y, Real K, Bernstein BM,
Japour AJ, Sun E, Rode RA. Identification of genotypic changes in human
immunodeficiency virus protease that correlate with reduced susceptibility to
the protease inhibitor lopinavir among viral isolates from protease inhibitor-
experienced patients. J Virol. 2001 Aug;75(16):7462-9
19. Hermans P, Schimt J, Kabeya K, et al. Virological response to salvage
therapy at 6 months in patients with B and non-B subtypes. In: Proceedings
of the Ninth Conference on Retroviruses and Opportunistic Infections,
Seattle, WA, 2002 [Abstract 427].
20. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-
blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to
nelfinavir plus stavudine and lamivudine. J Infect Dis 2004;189(1):51-60.
21. Ananworanich J, Hirschel B, Sirivichayakul S, et al. Absence of resistance
mutations in antiretroviral-naive patients treated with ritonavir-boosted
saquinavir. Antivir Ther 2006;11(5):631-5.
22. Eron J, Jr., Yeni P, Gathe J, Jr., et al. The KLEAN study of fosamprenavir-
ritonavir versus lopinavir-ritonavir, each in combination with abacavir-
lamivudine, for initial treatment of HIV infection over 48 weeks: a
randomised non-inferiority trial. Lancet 2006;368(9534):476-82.
23. Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD,
Godfrey C, Bastow B, Ray MG, Wang H, Coombs RW, McKinnon J, Mellors
JW; AIDS Clinical Trials Group 5201 Study Team. Regimen simplification to
atazanavir-ritonavir alone as maintenance antiretroviral therapy after
sustained virologic suppression. JAMA. 2006 Aug 16;296(7):806-14
24. Norton M, Delaugere C, Batot G, Delfraissy J, Rouzioux C. Drug resistance
outcomes in a trial comparing lopinavir/ritonavir monotherapy to LPV/r +